| Siliq (brodalumab) / Bausch Health |
NCT03240809: An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects |
|
|
| Recruiting | 4 | 16 | US | Brodalumab | Bausch Health Americas, Inc. | Psoriasis | 07/24 | 07/24 | | |
| Recruiting | 4 | 384 | Europe, RoW | Brodalumab | LEO Pharma, LEO Pharma A/S | Psoriasis Vulgaris | 09/25 | 01/26 | | |
NCT03957681: A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis |
|
|
| Active, not recruiting | 3 | 100 | Japan | KHK4827, Placebo | Kyowa Kirin Co., Ltd. | Moderate to Severe Systemic Sclerosis | 10/20 | 02/24 | | |
|
NCT04061252: A Study of KHK4827 in Subjects With Palmoplantar Pustulosis |
|
|
| Completed | 3 | 126 | Japan | KHK4827, Placebo | Kyowa Kirin Co., Ltd. | Palmoplantar Pustulosis | 08/21 | 08/22 | | |
| Terminated | 3 | 12 | Europe | Brodalumab, Kyntheum®, Ustekinumab, Stelara®, Placebo | LEO Pharma | Psoriasis | 05/23 | 05/23 | | |
NCT04368403: A Study of KHK4827 in Patients With Systemic Sclerosis |
|
|
| Active, not recruiting | 1 | 8 | Japan | KHK4827 | Kyowa Kirin Co., Ltd. | Systemic Sclerosis | 01/19 | 02/24 | | |
CARE, NCT05132231: Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity |
|
|
| Recruiting | N/A | 500 | Canada | Brodalumab, Matched cohort | Bausch Health Americas, Inc. | Psoriasis | 06/24 | 06/24 | | |
NCT03254667: LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis |
|
|
| Enrolling by invitation | N/A | 3500 | US | Brodalumab, Comparator Drug (non-biologic IL-17 inhibitors) | Bausch Health Americas, Inc. | Psoriasis | 11/30 | 11/31 | | |